Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
|Articles|January 1, 1997
The American Journal of Managed Care
- January 1997
- Volume 3
- Issue 1
Bridging the Gap Between Managed Care and Academic Medicine: An Innovative Fellowship
Advertisement
Articles in this issue
almost 30 years ago
Implications of Managed Care Denials for Pediatric Inpatient Carealmost 30 years ago
Cost-Effectiveness of Sumatriptan in a Managed Care Populationalmost 30 years ago
An Innovative Approach to Reducing Medical Care Utilization and Expendituresalmost 30 years ago
To Tell the Truth: Disclosing the Incentives and Limits of Managed CareAdvertisement
Related to this article
Kidney Week 2026 abstracts show that AMKD progresses quickly in routine practice, with or without diabetes, despite background CKD therapy.
Insurance barriers were the top reason 4 in 10 people prescribed long-acting PrEP at a Missouri clinic never received it, an IDWeek 2026 poster found.
A retrospective study suggests strength exercise may be a safer option than endurance exercise for some people with ACM.
Infant flu protection from maternal vaccination varied by timing, while pediatric vaccination fell to 49.4%, experts report at IDWeek 2026.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
The pilot pairs grocery stipends and community health worker support with members who have unmanaged diabetes and unmet social needs.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
3
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
4
Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD
5